Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sanofi 2 ADR Representing Ord Shs SNY

Healthcare
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Recent & Breaking News (NDAQ:SNY)

It Affects Over 1.5 Million People in the UK. [1],[2] In a Survey, 80% Report that it Impacts their Mood, Mental Health and Well-Being. But What is Atopic Dermatitis?

PR Newswire Europe Non Regulatory May 15, 2018

Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period

GlobeNewswire May 14, 2018

Sanofi: Annual General Shareholders' Meeting of May 2, 2018

GlobeNewswire May 2, 2018

Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients

PR Newswire May 1, 2018

Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

GlobeNewswire April 30, 2018

FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

PR Newswire April 30, 2018

Benzinga's Daily Biotech Pulse: Intra-cellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences

Benzinga.com  April 27, 2018

Sanofi: First-quarter 2018 Business EPS up 1.4% at CER

PR Newswire April 27, 2018

Sanofi to Host Earnings Call

Accesswire April 27, 2018

FDA accepts for review Supplemental Biologics License Application for 0.5 mL dose of Fluzone® Quadrivalent (Influenza Vaccine) in children 6-35 months of age

PR Newswire April 25, 2018

Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business

GlobeNewswire April 17, 2018

New tools, support and information on insulin use now available to Canadians living with Type 2 diabetes aiming to maintain healthy blood glucose levels

Canada NewsWire April 12, 2018

Sanofi to invest €350 million in Canadian vaccine facility

GlobeNewswire April 12, 2018

Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes

GlobeNewswire March 29, 2018

Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018

GlobeNewswire March 29, 2018

Sanofi: Availability of the Pre-quarterly Results Communication

GlobeNewswire March 28, 2018

FDA approves Toujeo® Max SoloStar®

PR Newswire March 27, 2018

Sanofi successfully prices EUR 8 billion of bond issues

GlobeNewswire March 15, 2018

Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

Canada NewsWire March 10, 2018

Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need

PR Newswire March 10, 2018